HXL 04
Alternative Names: HXL-04Latest Information Update: 18 Jan 2021
Price :
$50 *
At a glance
- Originator Henlix Biotech
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factors modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 01 Jan 2021 Preclinical trials in Diabetic retinopathy in Taiwan (Parenteral) (Henlix Biotech pipeline, January 2021)
- 01 Jan 2021 Preclinical trials in Wet age-related macular degeneration in Taiwan (Parenteral) (Henlix Biotech pipeline, January 2021)
- 01 Jan 2021 Henlix Biotech files an IND application for Wet age related macular degeneration and Diabetic retinopathy (Henlix Biotech pipeline, January 2021)